2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice GuidelinesGraham R. Clinical Practice Guidelines We Can Trust. Washington D.C.: National Academies Press; 2011.

10.1016/j.jacc.2013.08.004

10.1161/CIRCULATIONAHA.113.004587

10.1542/peds.2009-2107C

10.1161/cir.0b013e31829e8776

National Cholesterol Education Program (US) National Heart Lung and Blood Institute National Institutes of Health. Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Bethesda MD: National Cholesterol Education Program National Heart Lung and Blood Institute National Institutes of Health; 2002. NIH Publication No. 02–5215.

10.1161/01.CIR.0000133317.49796.0E

10.1161/circ.106.25.3143

10.1056/NEJMoa1107579

10.1161/01.cir.0000437740.48606.d1

10.1161/01.cir.0000437741.48606.98

10.1002/14651858.CD009217.pub2

10.1016/S0140-6736(12)60367-5

10.1056/NEJMoa1001282

Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816.

10.1016/S0140-6736(02)09327-3

10.1001/jama.279.20.1615

10.1016/S0140-6736(06)69472-5

10.1016/j.amjcard.2008.02.056

10.1016/S0140-6736(10)61350-5

10.1016/j.amjcard.2008.10.029

10.1001/archinte.166.6.605

10.1111/j.1532-5415.2011.03786.x

10.1001/archinte.162.20.2269

10.1001/archinternmed.2011.32

10.1161/01.STR.0000254602.58896.d2

10.1093/gerona/60.4.491

10.1111/j.1532-5415.2011.03867.x

10.1111/j.1532-5415.2011.03523.x

10.1001/archinternmed.2011.424

10.1056/NEJMp1109283

10.1177/0272989X05280558

10.1056/NEJMsa012528

10.1037/0278-6133.15.5.332

10.1046/j.1525-1497.2000.06289.x

10.1001/jama.1995.03520390045031

10.7326/0003-4819-152-8-201004200-00005

10.1016/S0140-6736(02)11600-X

10.1007/s00415-009-5271-7

10.1111/j.1532-5415.2011.03721.x

10.1093/gerona/63.4.369

Hippisley-Cox J, Pringle M, Cater R, et al. Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. Br J Gen Pract. 2005;55:369–75.

10.1016/j.jacc.2011.02.014

10.1210/jc.2011-3213

10.1161/CIR.0b013e3182160726

10.1056/NEJMoa050461

10.1001/jama.294.19.2437

10.1056/NEJMoa040583

10.1056/NEJMoa0807646

10.1016/S0140-6736(05)67394-1

10.1016/j.atherosclerosissup.2004.08.031

10.1016/S0140-6736(12)61190-8

10.1093/eurheartj/ehr305

10.1056/NEJMoa052187

10.1111/j.1464-5491.2011.03542.x

10.1001/archinternmed.2011.351

10.2337/dc09-1444

10.2337/diacare.27.1.201

10.1056/NEJMsa073166

10.1161/circulationaha.109.192216

10.1016/j.jacc.2009.08.086

10.1016/j.atherosclerosis.2008.09.023

10.1186/1741-7015-11-7

Lescol (fluvastatin sodium) [prescribing information]. Novartis Pharmaceuticals. East Hanover, NJ; 2012.

Pravachol (pravastatin sodium) [prescribing information]. Bristol Myers Squibb Co. Princeton, NJ; 2012.

Livalo (pitivastatin) [prescribing information]. Kowa Pharmaceuticals. Montgomery, AL; 2012.

Zocor (Simvastatin) [prescribing information]. Merck & Co. Whitehouse Station, NJ; 2012.

Mevacor (Lovastatin) [prescribing information]. Merck & Co. Whitehouse Station, NJ; 2012.

Lipitor (atorvastatin calcium) [prescribing information]. Pfizer Inc. New York, NY; 2012.

Crestor (rosuvastatin calcium) [prescribing information]. AstraZeneca Pharmaceuticals. Wilmington, DE; 2013.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–89.

10.1056/NEJM199511163332001

10.1056/NEJM199610033351401

10.1056/NEJM199811053391902

10.1016/S0140-6736(04)16895-5

Deleted in press.

10.1056/NEJMoa061894

10.1056/NEJMoa061894

10.1016/j.amjcard.2012.04.062

Stone NJ Blum CB. Management of Lipids in Clinical Practice. 7th ed. Caddo OK: Professional Communications; 2008.

10.1016/S0140-6736(09)61965-6

10.1016/S0140-6736(11)60445-5

10.1001/jama.285.19.2486

10.1056/NEJMoa0810177

10.1056/NEJMoa0706201

10.1016/S0140-6736(08)61240-4

10.1056/NEJMoa043545

10.1210/jc.2009-2689

US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Rockville MD: US Food and Drug Administration; 2012.

US Food and Drug Administration. FDA Drug Safety Communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. Rockville MD: US Food and Drug Administration; 2010.

10.2337/dc13-S011

10.1016/S0140-6736(08)61930-3

10.1001/jama.285.13.1711

10.2337/dc05-2465

Deleted in Press.

10.1016/S0140-6736(10)61350-5

10.1016/j.jacc.2008.08.039

10.1016/j.amjmed.2006.07.033

10.1016/S0140-6736(04)15690-0

Roberts MD. Crestor (rosuvastatin calcium) NDA 21–336 JUPITER. Paper presented at US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Meeting December 15 2009. Gaithersburg MD: US Food and Drug Administration; 2009.

10.1001/jama.1975.03240160024021

10.1016/j.amjcard.2006.11.018

10.1016/j.amjcard.2008.02.039

10.1001/archinte.162.14.1568

10.1016/0002-9343(87)90692-9

10.1016/j.atherosclerosis.2008.02.009

10.1097/01.JCN.0000305061.88624.fc

10.1016/j.amjcard.2006.10.064

10.1016/j.ahj.2010.08.012

10.1016/S0002-8703(03)00367-3

10.1056/NEJM198711123172001

10.1001/jama.1984.03340270043026

10.1001/jama.1984.03340270029025

10.1056/NEJM199908053410604

10.1016/S0140-6736(05)67667-2

10.1093/eurheartj/eht055

10.1001/jama.292.11.1307

10.1016/j.jacc.2004.07.053

10.2337/dc05-2415

10.1185/030079902125000787

10.1056/NEJMoa011090

10.1001/jama.287.24.3215

10.1016/j.amjcard.2005.11.031

10.1016/S0140-6736(10)60310-8

10.1093/eurheartj/ehl220

10.7326/0003-4819-147-1-200707030-00002

10.1212/01.wnl.0000327339.55844.1a

10.1016/j.jacc.2007.11.072

10.1016/S0025-6196(11)60763-5

10.1056/NEJM199610033351401

10.1001/jama.288.23.2998

10.2337/diacare.28.5.1151

10.1111/j.1600-6143.2005.01105.x

10.1016/S0140-6736(08)60104-X

10.1016/j.amjcard.2007.08.033

10.1016/j.amjcard.2009.12.051

10.1001/archinternmed.2010.182

10.1136/bmj.b2376

10.1111/j.1751-7141.2009.00059.x

10.1161/CIRCULATIONAHA.106.671826

10.1111/j.1365-2125.2007.02959.x

10.1001/jama.2011.860

10.1016/S0735-1097(86)80293-5

10.1136/hrt.2010.215046